Van Poznak C - Search Results

1

Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases.

Morikawa A, de Stanchina E, Pentsova E, Kemeny MM, Li BT, Tang K, Patil S, Fleisher M, Van Poznak C, Norton L, Seidman AD. Morikawa A, et al. Among authors: van poznak c. Clin Cancer Res. 2019 Jul 1;25(13):3784-3792. doi: 10.1158/1078-0432.CCR-18-3502. Epub 2019 Apr 15. Clin Cancer Res. 2019. PMID: 30988080 Free PMC article. Clinical Trial.

2

Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial.

Van Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K, Borgen P, Gollub M, Bacotti D, Yao TJ, Bloch R, Ligueros M, Sonenberg M, Norton L, Hudis C. Van Poznak C, et al. Among authors: van zee k. Breast Cancer Res Treat. 2001 Apr;66(3):239-48. doi: 10.1023/a:1010686204736. Breast Cancer Res Treat. 2001. PMID: 11510695 Clinical Trial.

3

How are bisphosphonates used today in breast cancer clinical practice?

Van Poznak C. Van Poznak C. Semin Oncol. 2001 Aug;28(4 Suppl 11):69-74. doi: 10.1053/sonc.2001.25445. Semin Oncol. 2001. PMID: 11544580 Review.

4

Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.

Van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidman AD. Van Poznak C, et al. J Clin Oncol. 2002 May 1;20(9):2319-26. doi: 10.1200/JCO.2002.08.125. J Clin Oncol. 2002. PMID: 11981003

5

HER2 testing and correlation with efficacy of trastuzumab therapy.

Fornier M, Risio M, Van Poznak C, Seidman A. Fornier M, et al. Among authors: van poznak c. Oncology (Williston Park). 2002 Oct;16(10):1340-8, 1351-2; discussion 1352, 1355-8. Oncology (Williston Park). 2002. PMID: 12435204 Review.

6

Critical review of current treatment strategies for advanced hormone insensitive breast cancer.

Van Poznak C, Seidman AD. Van Poznak C, et al. Cancer Invest. 2002;20 Suppl 2:1-14. doi: 10.1081/cnv-120014881. Cancer Invest. 2002. PMID: 12442344 Review.

7

The use of bisphosphonates in patients with breast cancer.

Van Poznak CH. Van Poznak CH. Cancer Control. 2002 Nov-Dec;9(6):480-9. doi: 10.1177/107327480200900605. Cancer Control. 2002. PMID: 12514566 Free article. Review.

8

Clinical management of osteoporosis in women with a history of breast carcinoma.

Van Poznak C, Sauter NP. Van Poznak C, et al. Cancer. 2005 Aug 1;104(3):443-56. doi: 10.1002/cncr.21201. Cancer. 2005. PMID: 15968687 Free article. Review.

9

Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.

Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD. Modi S, et al. Among authors: van poznak c. Cancer Invest. 2005;23(6):483-7. doi: 10.1080/07357900500201301. Cancer Invest. 2005. PMID: 16203655

10

The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer.

Van Poznak C. Van Poznak C. Cancer Invest. 2006 Feb;24(1):110-2. doi: 10.1080/07357900500449652. Cancer Invest. 2006. PMID: 16467002

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

139 results

Search Page